← Russell 3000 cross-section

GKOS GLAUKOS Corp

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$10.7bn
Revenue TTM
$613m
Net income TTM
$-188m
Free cash flow
$-12m
Composite score
44.5
Sector rank
#681

Valuation

P / E
EV / EBITDA
EV / sales
17.3
FCF yield
-0.11%
Earnings yield vs 10-yr
-6.48pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-30.7%
EBITDA margin
-24.7%
ROE
-27.6%
ROIC
-34.0%
Revenue growth
41.5%

Insider activity, last 90 days

Net open-market
$-19.90m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Unrealized losses on available-for-sale debt securities as of June 30, 2026 and December 31, 2025 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, the Company did not record an allowance for credit losses with respect to these investments as of June 30, 2026 and December 31, 2025. …GLAUKOS Corp, 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →